Search Results | Blood | American Society of Hematology

1-20 of 710

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade

Blood (2019) 134 (Supplement_1): 1493.

DOI: https://doi.org/10.1182/blood-2019-131904

Published: 2019

Journal Articles

Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma

Paolo Strati, MD, Ralph J. Johnson, PhD, Sheryl G Forbes, Loretta J. Nastoupil, MD MSc, Felipe Samaniego, MD, Eric Davis, MD, Michael R Green, PhD, Luis Fayad, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Michael L. Wang, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD

Blood (2019) 134 (Supplement_1): 1533.

DOI: https://doi.org/10.1182/blood-2019-129311

Published: 2019

Journal Articles

French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up

Blood (2019) 134 (Supplement_1): 1537.

DOI: https://doi.org/10.1182/blood-2019-127560

Published: 2019

Journal Articles

AVM0703, a New Treatment Option for Lymphoma Patients

Theresa Deisher, PhD, Margaret Taylor, Arya Ashok, PhD, Peter Jarzyna, PhD, Yumna Zahid, Stephanie Lee-Diaz, Colleen Rylatt, Kendra Poulin, Vaishnavi Parthasarathy

Blood (2019) 134 (Supplement_1): 5308.

DOI: https://doi.org/10.1182/blood-2019-128812

Published: 2019

Journal Articles

Insulin-like Growth Factor-1-Induced Epithelial-Mesenchymal Transition Promotes Multiple Myeloma Progression

Yue Peng, Xiaman Wang, Ying Shen, MD, Fangmei Li, PhD, Ru Zhang, MD, Yachun Jia, Aili He

Blood (2019) 134 (Supplement_1): 5541.

DOI: https://doi.org/10.1182/blood-2019-127714

Published: 2019

Journal Articles

A Single Institution Experience of Bortezomib for Gvhd in a Pediatric HSCT Population

Devangi Shah, Jennifer Reichbach Douglas, DNP, APRN, CPHON, Jumana Ashy, Gregory Suhrheinrich, Edward Dela Ziga, MD, Asha B. Pillai, MD, Julio C Barredo, MD, Warren Alperstein, MD

Blood (2019) 134 (Supplement_1): 5680.

DOI: https://doi.org/10.1182/blood-2019-125884

Published: 2019

Journal Articles

Development of Novel Anti-CD10 Target Modules for Redirection of Universal CAR T Cells Against CD10-Positive Malignancies

Anja Feldmann, PhD, Stefanie Koristka, PhD, Claudia Arndt, PhD, Liliana Raquel Loureiro, PhD, Ralf Bergmann, PhD, Nicole Berndt, PhD, Anja Hoffmann, Justyna Jureczek, Nicola Mitwasi, Martin Bornhaeuser, MD, Václav Hořejší, Michael Bachmann, MD

Blood (2019) 134 (Supplement_1): 5612.

DOI: https://doi.org/10.1182/blood-2019-128193

Published: 2019

Journal Articles

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Zachary Davis, PhD BS, Martin Felices, PhD, Todd R Lenvik, Sujan Badal, Peter Hinderlie, Bruce R. Blazar, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 621.

DOI: https://doi.org/10.1182/blood-2019-127261

Published: 2019

Journal Articles

RIG-I Activation Is Critical for Responsiveness to Checkpoint Blockade

Simon Heidegger, MD, Alexander Wintges, Florian Stritzke, Katja Steiger, Paul-Albert Koenig, Thomas Engleitner, Julius Clemens Fischer, Vladimir Makarov, Christof Winter, Roland Rad, Marcel R.M. van den Brink, MD PhD, Jürgen Ruland, Florian Bassermann, MD PhD, Timothy Chan, Tobias Haas, MD, Hendrik Poeck, MD

Blood (2019) 134 (Supplement_1): 624.

DOI: https://doi.org/10.1182/blood-2019-128724

Published: 2019

Journal Articles

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

Blood (2019) 134 (Supplement_1): 830.

DOI: https://doi.org/10.1182/blood-2019-131494

Published: 2019

Journal Articles

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Blood (2019) 134 (Supplement_1): 49.

DOI: https://doi.org/10.1182/blood-2019-122374

Published: 2019

Journal Articles

Biomarker Assessment of Venous Thromboembolism in Cancer Patients Receiving Checkpoint Blockade

Shadi Swaidani, MD PhD, Joanna Roopkumar, MBBS, MPH, Young Jun-Shim, PhD, Cathy Charles, Slato Paul, Suman Kundu, MBA, Pauline Funchain, MD, Patricia Rayman, Paul G. Pavicic, C. Marcela Diaz-Montero, PhD, Alok A Khorana, MD, Keith R McCrae, MD

Blood (2019) 134 (Supplement_1): 3648.

DOI: https://doi.org/10.1182/blood-2019-130911

Published: 2019

Journal Articles

Risk of Intracerebral Hemorrhage with and without Anticoagulation in Patients with Brain Metastasis: The Cleveland Clinic Experience

Tariq Zuheir Kewan, MD, Shafia Rahman, MBBS, Fahrettin Covut, MD, Ramsha Ahmed, MD, Seba Hasan, Yihong Zhou, MD, Alok A Khorana, MD

Blood (2019) 134 (Supplement_1): 3683.

DOI: https://doi.org/10.1182/blood-2019-131758

Published: 2019

Journal Articles

Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis

Smith Giri, MBBS, Peter Barth, MD, Luciano J. Costa, MD PhD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 1862.

DOI: https://doi.org/10.1182/blood-2019-131231

Published: 2019

Journal Articles

Incidence and Risk Factors of De Novo Skin Cancer in a Contemporary Cohort of Hematopoietic Cell Transplantation Survivors

Jennifer Berano Teh, Farah Abdulla, MD, Kelly Peng, Liezl Atencio, Alicia Gonzales, Meagan Echevarria, Alex Iukuridze, Alan Geller, Heeyoung Kim, Lennie Wong, PhD, Stephen J Forman, MD, Ryotaro Nakamura, MD, Badri Modi, MD, Saro H. Armenian, DO, MPH

Blood (2019) 134 (Supplement_1): 2011.

DOI: https://doi.org/10.1182/blood-2019-124993

Published: 2019

Journal Articles

Chromosome 1q Amplification Is Associated with a History of Prior Malignancies Among Patients Newly Diagnosed with Multiple Myeloma

Elizabeth B Lamont, MD MS, MMSc, Andrew J. Yee, MD, Stuart L. Goldberg, MD, Andrew D Norden, MD MPH, MBA

Blood (2019) 134 (Supplement_1): 2193.

DOI: https://doi.org/10.1182/blood-2019-125407

Published: 2019

Journal Articles

Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939

Martine Humbert, PhD, Armelle Goubard, PhD, Colin Mansfield, PhD, Olivier Hermine, MD PhD, Patrice Dubreuil, PhD, The AB8939 Study Group

Blood (2019) 134 (Supplement_1): 2075.

DOI: https://doi.org/10.1182/blood-2019-122540

Published: 2019

Journal Articles

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Alex F. Herrera, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Matthew Mei, MD, Saro H. Armenian, DO, MPH, Justin Darrah, MD, Liana Nikolaenko, MD, Robert W. Chen, MD, Lacolle Peters, Neena Kennedy, Steven Rosen, MD, Stephen J Forman, MD, Larry W Kwak, MD PhD

Blood (2019) 134 (Supplement_1): 759.

DOI: https://doi.org/10.1182/blood-2019-123163

Published: 2019

Journal Articles

Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]

Philip A. Thompson, MBBS, Michael J Keating, MBBS, Nitin Jain, MD, Alessandra Ferrajoli, MD, Tapan M. Kadia, MD, Prithviraj Bose, MD, William G. Wierda, MD PhD

Blood (2019) 134 (Supplement_1): 358.

DOI: https://doi.org/10.1182/blood-2019-129230

Published: 2019

Journal Articles

Transcriptome Alterations of Isolated Primary Bone Marrow Endothelial Cells Provide Insigt to MGUS and Multiple Myeloma Pathobiology

Sandro Bräunig, MSc, Dimitra Zacharaki, PhD, Hongzhe Li, PhD, Hooi Ching Lim, PhD, Stefan Lang, PhD, Thoas Fioretos, MD PhD Prof., Stefan Scheding, MD

Blood (2019) 134 (Supplement_1): 4373.

DOI: https://doi.org/10.1182/blood-2019-128024

Published: 2019

2 3 4 5

NARROW

Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade

Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma

French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up

AVM0703, a New Treatment Option for Lymphoma Patients

Insulin-like Growth Factor-1-Induced Epithelial-Mesenchymal Transition Promotes Multiple Myeloma Progression

A Single Institution Experience of Bortezomib for Gvhd in a Pediatric HSCT Population

Development of Novel Anti-CD10 Target Modules for Redirection of Universal CAR T Cells Against CD10-Positive Malignancies

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

RIG-I Activation Is Critical for Responsiveness to Checkpoint Blockade

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Biomarker Assessment of Venous Thromboembolism in Cancer Patients Receiving Checkpoint Blockade

Risk of Intracerebral Hemorrhage with and without Anticoagulation in Patients with Brain Metastasis: The Cleveland Clinic Experience

Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis

Incidence and Risk Factors of De Novo Skin Cancer in a Contemporary Cohort of Hematopoietic Cell Transplantation Survivors

Chromosome 1q Amplification Is Associated with a History of Prior Malignancies Among Patients Newly Diagnosed with Multiple Myeloma

Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]

Transcriptome Alterations of Isolated Primary Bone Marrow Endothelial Cells Provide Insigt to MGUS and Multiple Myeloma Pathobiology

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only